藥碼
VIT09
藥名
Dextrose 50% 注射 大瓶 500 mL
英文商品名
Vitagen 50% 大瓶 500mL
中文商品名
美達研注射液 50% 瓶 500mL
螢幕名
【大瓶】Vitagen 50% 500 mL
劑型
Inj
規格
成分
藥理分類
Caloric Drugs
健保碼
NC06067277
ATC碼
適應症
| #高警訊藥品 |
Antidote, Hypoglycemia; Intravenous Nutritional Therapy
藥理
Dextrose, a monosaccharide, is a source of calories and fluid for patients unable to obtain an adequate oral intake; may decrease body protein and nitrogen losses; promotes glycogen deposition in the liver. When used in the treatment of hyperkalemia (combined with insulin), dextrose stimulates the transient uptake of potassium by cells, especially in muscle tissue, lowering serum potassium.
藥動學
禁忌症
Hypersensitivity to dextrose, corn or corn products, or any component of the formulation; hypertonic solutions in patients with intracranial or intraspinal hemorrhage; severe dehydration; hypertonic solutions in patients with alcohol withdrawal; clinically significant hyperglycemia; anuria; hepatic coma; dextrose solutions without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.
Contraindications may vary by product (also refer to manufacturer's labeling).
Contraindications may vary by product (also refer to manufacturer's labeling).
懷孕分類
Dextrose has been used during labor and delivery. Exposure during pregnancy is not expected to cause major birth defects, miscarriage, or adverse outcomes to the fetus or mother when used during pregnancy.
哺乳分類
Glucose is present in human milk (IOM 2005).
Glucose concentrations in breast milk were found to increase following administration of IV dextrose to lactating patients. Concentrations were higher in lactating patients with diabetes than lactating patients without diabetes (Jovanovic-Peterson 1989).
Glucose concentrations in breast milk were found to increase following administration of IV dextrose to lactating patients. Concentrations were higher in lactating patients with diabetes than lactating patients without diabetes (Jovanovic-Peterson 1989).
副作用
劑量和給藥方法
劑量 :
1. Calcium channel blocker or beta-blocker overdose/toxicity (adjunctive agent) (off-label use)
For use only as an adjuvant component of high-dose insulin therapy (HDIT). HDIT is used for patients who are refractory to initial therapies (eg, atropine, calcium, vasopressors).
Patients with existing hypoglycemia (baseline blood glucose <200 mg/dL) :
25 g (50 mL D50W) as a single bolus dose followed by a continuous infusion of 0.5 g/kg/hour when HDIT is initiated; titrate dextrose to maintain blood glucose concentration >100 mg/dL. Hold dextrose for blood glucose concentration 200 mg/dL
Patients without existing hypoglycemia :
Initiate a continuous infusion of 0.5 g/kg/hour when HDIT is initiated; titrate dextrose infusion to maintain blood glucose concentration >100 mg/dL. Hold dextrose for blood glucose concentration 200 mg/dL
2. Hyperkalemia, severe/emergent (adjunctive agent) (off-label use)
Used as an adjunct to insulin therapy. Consider omitting dextrose from regimen if blood glucose is ≥ 250 mg/dL
IV: 25 to 50 g dextrose over 5 minutes; only administer along with separate administration of IV insulin (eg, regular insulin); repeat as needed. After initial dose of dextrose, some experts administer 10% dextrose continuous IV infusion at 50 to 100 mL/hour for ~5 hours.
Note : Monitor blood glucose every hour for up to 6 hours after insulin has been administered
3. Hypoglycemia
- blood glucose <70 mg/dL (or <100 mg/dL in neurologic injury patients)
- discontinue insulin therapy (if receiving) and administering 10 to 20 g (20 to 40 mL of 50% solution) IV
- repeat blood glucose measurement in 15 minutes with repeat dextrose administration as necessary; avoid overcorrection.
用法 :
1. 皮下注射 : 將注射液注射於大腿部皮下為佳
2. 靜脈內注射 : 尤其是滲透療法及使用大量的糖分時以本法為便利
注意事項 :
(1) 高張液行靜脈內注射時要在可能範圍內緩慢地施行，大量注射時將該液用溫水加溫後使用為宜。
(2) 靜脈內注射時，因體質之不同，注射之後，有時可能誘發輕度的惡寒戰慄或發燒，這時使用強心劑，或令安靜即可。
(3) 對於糖尿病重症患者，宜避免使用本劑為佳。
1. Calcium channel blocker or beta-blocker overdose/toxicity (adjunctive agent) (off-label use)
For use only as an adjuvant component of high-dose insulin therapy (HDIT). HDIT is used for patients who are refractory to initial therapies (eg, atropine, calcium, vasopressors).
Patients with existing hypoglycemia (baseline blood glucose <200 mg/dL) :
25 g (50 mL D50W) as a single bolus dose followed by a continuous infusion of 0.5 g/kg/hour when HDIT is initiated; titrate dextrose to maintain blood glucose concentration >100 mg/dL. Hold dextrose for blood glucose concentration 200 mg/dL
Patients without existing hypoglycemia :
Initiate a continuous infusion of 0.5 g/kg/hour when HDIT is initiated; titrate dextrose infusion to maintain blood glucose concentration >100 mg/dL. Hold dextrose for blood glucose concentration 200 mg/dL
2. Hyperkalemia, severe/emergent (adjunctive agent) (off-label use)
Used as an adjunct to insulin therapy. Consider omitting dextrose from regimen if blood glucose is ≥ 250 mg/dL
IV: 25 to 50 g dextrose over 5 minutes; only administer along with separate administration of IV insulin (eg, regular insulin); repeat as needed. After initial dose of dextrose, some experts administer 10% dextrose continuous IV infusion at 50 to 100 mL/hour for ~5 hours.
Note : Monitor blood glucose every hour for up to 6 hours after insulin has been administered
3. Hypoglycemia
- blood glucose <70 mg/dL (or <100 mg/dL in neurologic injury patients)
- discontinue insulin therapy (if receiving) and administering 10 to 20 g (20 to 40 mL of 50% solution) IV
- repeat blood glucose measurement in 15 minutes with repeat dextrose administration as necessary; avoid overcorrection.
用法 :
1. 皮下注射 : 將注射液注射於大腿部皮下為佳
2. 靜脈內注射 : 尤其是滲透療法及使用大量的糖分時以本法為便利
注意事項 :
(1) 高張液行靜脈內注射時要在可能範圍內緩慢地施行，大量注射時將該液用溫水加溫後使用為宜。
(2) 靜脈內注射時，因體質之不同，注射之後，有時可能誘發輕度的惡寒戰慄或發燒，這時使用強心劑，或令安靜即可。
(3) 對於糖尿病重症患者，宜避免使用本劑為佳。
小兒調整劑量
1. Hypoglycemia
Infants and Children
Dextrose 25% solution (0.25 g/mL): IV, Intraosseous: 0.5 to 1 g/kg/dose (2 to 4 mL/kg/dose of 25% solution); maximum dose: 25 g/dose.
Adolescents
Dextrose 50% solution (0.5 g/mL): IV, Intraosseous: 0.5 to 1 g/kg/dose (1 to 2 mL/kg/dose of 50% solution); maximum dose: 25 g/dose
Hyperkalemia, treatment
Infants, Children, and Adolescents: IV: 0.5 to 1 g/kg/dose combined with regular insulin over 15 to 30 minutes; dose may be repeated; in some cases, a continuous IV infusion may be necessary. In adults, the usual initial dose of dextrose is 25 to 50 g
Parenteral nutrition
Infants
IV : Initial : 6 to 8 mg/kg/minute; usual daily increase: 1 to 2 mg/kg/minute as tolerated; usual goal: 10 to 14 mg/kg/minute; maximum daily rate: 18 mg/kg/minute.
Children ≤ 10 years
IV : Initial : 3 to 6 mg/kg/minute; usual daily increase: 1 to 2 mg/kg/minute; usual goal as tolerated: 8 to 10 mg/kg/minute.
Children >10 years and Adolescents
IV: Initial: 2.5 to 3 mg/kg/minute; usual daily increase: 1 to 2 mg/kg/minute as tolerated; usual goal: 5 to 6 mg/kg/minute.
Infants and Children
Dextrose 25% solution (0.25 g/mL): IV, Intraosseous: 0.5 to 1 g/kg/dose (2 to 4 mL/kg/dose of 25% solution); maximum dose: 25 g/dose.
Adolescents
Dextrose 50% solution (0.5 g/mL): IV, Intraosseous: 0.5 to 1 g/kg/dose (1 to 2 mL/kg/dose of 50% solution); maximum dose: 25 g/dose
Hyperkalemia, treatment
Infants, Children, and Adolescents: IV: 0.5 to 1 g/kg/dose combined with regular insulin over 15 to 30 minutes; dose may be repeated; in some cases, a continuous IV infusion may be necessary. In adults, the usual initial dose of dextrose is 25 to 50 g
Parenteral nutrition
Infants
IV : Initial : 6 to 8 mg/kg/minute; usual daily increase: 1 to 2 mg/kg/minute as tolerated; usual goal: 10 to 14 mg/kg/minute; maximum daily rate: 18 mg/kg/minute.
Children ≤ 10 years
IV : Initial : 3 to 6 mg/kg/minute; usual daily increase: 1 to 2 mg/kg/minute; usual goal as tolerated: 8 to 10 mg/kg/minute.
Children >10 years and Adolescents
IV: Initial: 2.5 to 3 mg/kg/minute; usual daily increase: 1 to 2 mg/kg/minute as tolerated; usual goal: 5 to 6 mg/kg/minute.
腎功能調整劑量
No dosage adjustment necessary
肝功能調整劑量
There are no dosage adjustments provided in the manufacturer's labeling.
安定性
Stable at room temperature; protect from freezing and extreme heat.
藥袋資訊
臨床用途
低血糖，葡萄糖製劑
主要副作用
依指示使用少有副作用發生
泡製方法
儲存方式
請置於 15-30℃ 乾燥處儲存
注意事項
其他說明
藥局 g3 | 小庫 B4 | 藥庫 注F23
藥品外觀
顏色
形狀
剝痕
標記1
標記2
其他
健保藥價
80
自費價
106.4
仿單
資料庫
健保給付規定
## 資料使用與著作權聲明 本網站提供之藥品資訊，主要供醫療照護、藥事服務、衛教及一般資訊查詢使用。網站內容包含藥品名稱、成分、劑型、規格、適應症、使用方式、劑量、注意事項及其他相關資訊，實際內容依各藥品資料來源及本院資料建置情形而定。 一、醫療使用聲明 本網站所提供之藥品資訊僅供參考，不應單獨作為診斷、治療、處方調整、停藥或自行用藥之依據。 藥品之實際適應症、使用方法、使用劑量、使用頻率、療程及相關注意事項，應依個別病人之病情、年齡、肝腎功能、合併用藥及其他臨床狀況，由醫師或其他具資格之醫療專業人員進行專業判斷。 病人實際使用藥品時，請以醫師處方、藥袋標示及醫療專業人員之指示為依歸。請勿僅依本網站資訊自行增加、減少、停止或改變藥品使用方式及劑量。 如網站資訊與醫師處方、藥袋標示或醫療專業人員指示有所不同，應優先依醫師處方及醫療專業人員之個別指示使用。 二、資料來源與更新 本網站藥品資訊參考藥品資訊資料庫、主管機關核准之藥品仿單、藥品許可證資料、藥品製造或供應廠商提供之資料、本院藥品管理資料，以及其他經評估之專業資訊來源。 藥品資訊可能因主管機關核准內容、藥品許可證、仿單、供應狀況或臨床建議更新而有所變動，本網站將依實際作業情形進行維護與更新。 如需確認最新藥品核准資訊，應以主管機關公告、最新版藥品仿單及醫療專業人員判斷為準。 三、資料使用範圍 本網站內容可供個人查詢、醫療照護、衛教及非商業性學習使用。 使用者引用或轉載本網站內容時，應註明資料來源，並保留原有內容之完整性及必要之醫療警語，不得任意變更、變更原意或其他可能造成錯誤醫療理解之方式使用。 未經授權，不得將本網站內容大量重製、建立資料庫、進行商業性再利用，或以其他方式侵害相關著作權或其他權利。 四、著作權及第三方資料 本網站由本院自行製作之文字、編排、圖表、圖示及其他內容，其著作權或相關權利依著作權法及其他相關法令受到保護。 網站中引用之藥品仿單、藥品圖片、商標、產品名稱、主管機關資料或其他第三方資料，其著作權、商標權或其他相關權利仍歸原權利人所有。 本網站對第三方資料之使用，以醫療資訊提供、教育、研究或其他合法使用目的為原則，相關權利仍應依原資料來源及相關法令辦理。 五、責任範圍 本網站致力於維持資料之正確性與完整性，但藥品資訊可能隨核准事項、臨床資訊及供應狀況變更。 使用者因個別疾病、用藥或治療問題需要醫療判斷時，應洽詢醫師、藥師或其他適當之醫療專業人員。 本網站提供之一般性藥品資訊，無法取代醫療專業人員依個別病人狀況所作之醫療評估、處方及用藥指導。 六、聲明內容之調整 本院得依相關法令、資料來源、網站功能及實際作業需要，適時修訂本聲明內容。